Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial

PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria

The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines

Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states

The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives

Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%

The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients